A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
=== Sinai === Since at least the First Dynasty (3000 BCE) in ancient Egypt, and possibly before then, turquoise was used by the Egyptians and was mined by them in the Sinai Peninsula. This region was known as the Country of Turquoise by the native Monitu. There are six mines in the peninsula, all on its southwest coast, covering an area of some 650 km2 (250 sq mi). The two most important of these mines, from a historical perspective, are Serabit el-Khadim and Wadi Maghareh, believed to be among the oldest of known mines. The former mine is situated about 4 kilometres from an ancient temple dedicated to the deity Hathor. The turquoise is found in sandstone that is, or was originally, overlain by basalt. Copper and iron workings are present in the area. Large-scale turquoise mining is not profitable today, but the deposits are sporadically quarried by Bedouin peoples using homemade gunpowder. In the rainy winter months, miners face a risk from flash flooding; even in the dry season, death from the collapse of the haphazardly exploited sandstone mine walls may occur. The colour of Sinai material is typically greener than that of Iranian material but is thought to be stable and fairly durable. Often referred to as "Egyptian turquoise", Sinai material is typically the most translucent, and under magnification, its surface structure is revealed to be peppered with dark blue discs not seen in material from other localities.
== External links == Quantum Dots: Technical Status and Market Prospects Quantum dots that produce white light could be the light bulb's successor Single quantum dots optical properties Quantum dot on arxiv.org Quantum Dots Research and Technical Data Simulation and interactive visualization of Quantum Dots wave function
=== Witnesses === Afraid of being kidnapped and missing Mendonça, one of the boy's friend at school tried to commit suicide, two months after the disappearance. In the crime's reconstitution, Dias could not explain what he did between 14 (2 P.M) and 18 (6 P.M) hours on the day Mendonça disappeared. With the reconstitution it was proven that the investigation let leads and important witnesses slip by. The inspectors did not want to explain to the press the reason why they devalued Alcina Dias' testimony. A man that worked in a gas station guaranteed that at the time of the disappearance he saw Mendonça, in the centre of the village of Lousada, walking next to two other boys. The court questioned the witness about his statements to the GNR the day following the disappearance, where he said he saw two children passed by on bikes, but that neither was Mendonça. The witness insisted that he could not remember giving the testimony to GNR, even thought his signature was in the records. They also heard a witness that said they saw Mendonça's bicycle at 16 (4 P.M) hours. Without being identified, a boy that was 14 at the time of the disappearance, told RTP that PJ did not value the different testimonies given to the police. The witness, along with four other young people, was waiting for Mendonça to arrive to play football. When Mendonça got there he said he was not going to play anymore, hid his bike and got in the car. In 2003, in the Casa Pia Process, a man said that he was with Mendonça in a pension for sexual meetings, in the end of January 2001.
Sources: en.wikipedia.org
== Awards and honors == Agnes Fay Morgan Research Award, Iota Sigma Pi, 2019 Marshall University College of Science Distinguished Alumni Award, 2019 Eli Lilly Young Investigator Award in Analytical Chemistry, 2018 US HUPO Robert J. Cotter New Investigator Award, 2018 NSF CAREER Award, 2015 Arthur C. Neish Young Investigator Award, 2014 NSF Graduate Research Fellowship, 2002-2005
, not all individuals of the population have been removed, so some must remain susceptible. A driving force leading to the end of an epidemic is a decline in the number of infectious individuals. The epidemic does not typically end because of a complete lack of susceptible individuals. The role of both the basic reproduction number and the initial susceptibility are extremely important. In fact, upon rewriting the equation for infectious individuals as follows:
The New Zealand Defence Force proposes disestablishing 697 civilian roles as part of a restructuring process. 23 March: Hundreds of protesters gather outside the New Zealand Parliament to protest against the Government's plans to review the prescription of puberty blockers in "gender affirming care." New Zealand First leader and Deputy Prime Minister Winston Peters delivers a state of the nation speech at the James Hay Theatre in Christchurch, focusing on alleged wokeism and DEI issues. The event is picketed by both pro and anti-greyhound racing, pro-Palestinian and pro-Israel protesters. Police arrest 10 individuals for disrupting the event. 25 March: The High Court rejects the Whangārei District Council's bid to challenge the Director-General of Health's order to fluoridate its water supply. A magnitude 6.8 earthquake hits off the coast of Southland, producing a 10 cm (3.9 in)-tsunami. Cracks in the Dunedin Gasworks Museum were later found and may have been caused by the earthquake. The Tararua District Council issues a boil water notice in Woodville after rodent feces were found in the rafters of the town's reservoir building. 26 March: Queenstown residents protest against a decision by the Queenstown Lakes District Council to discharge treated sewage into the Shotover River. Mental Health Minister Matt Doocey acknowledges that Police accidentally sent an 11-year old autistic girl to a mental institution following a case of mistaken identity. The girl received at least two doses of anti-psychotic medicine.
In 1957, Berni Alder and Thomas Wainwright used an IBM 704 computer to simulate perfectly elastic collisions between hard spheres. In 1960, in perhaps the first realistic simulation of matter, J.B. Gibson et al. simulated radiation damage of solid copper by using a Born–Mayer type of repulsive interaction along with a cohesive surface force. In 1964, Aneesur Rahman published simulations of liquid argon that used a Lennard-Jones potential; calculations of system properties, such as the coefficient of self-diffusion, compared well with experimental data. Today, the Lennard-Jones potential is still one of the most frequently used intermolecular potentials. It is used for describing simple substances (a.k.a. Lennard-Jonesium) for conceptual and model studies and as a building block in many force fields of real substances.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.